FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964017448> ?p ?o ?g. }

• W2964017448 endingPage "15" @default.
• W2964017448 startingPage "1" @default.
• W2964017448 abstract "Mesenchymal stromal cells (MSCs) have become the most commonly used adult stem cells in regenerative medicine. Preclinical studies have shown that MSCs-based therapy is a potential new treatment approach for neurological diseases. Intrathecal injection has unique feature which allows stem cells to directly migrate to the lesion site in patients with central nervous system (CNS) diseases. In this study, we evaluate the safety and feasibility of intrathecal allogeneic bone marrow-derived MSCs (BM-MSCs) in patients with neurological diseases. This open-label clinical study included 37 patients (14 diseases). Eligible patients underwent a baseline assessment and were intrathecally injected with allogeneic BM-MSCs (<mml:math xmlns:mml=http://www.w3.org/1998/Math/MathML id=M1><mml:mn>1</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msup><mml:mtext> </mml:mtext><mml:mtext>cells</mml:mtext><mml:mo>/</mml:mo><mml:mtext>kg</mml:mtext></mml:math>, 4 consecutive treatments at 1-week intervals). After four infusions, the patients were followed up for at least 6 months. Adverse events, cerebrospinal fluid (CSF) test results, clinical symptoms, physical examination, and haematological and imaging examinations were used to assess the safety and feasibility of the treatment. Also, we performed a systematic review of the safety of all types of intrathecal stem cells and compared our result to previous studies. In our study, the highest adverse event was a slight ache at the injection site (4.11%), followed by fever (3.42%) and mild headache (2.05%). No severe adverse events were reported. After the intrathecal injections, the white blood cell (WBC) counts in the CSF increased in 30 patients and the protein concentration in the CSF exceeded the normal range in 26 patients, while other CSF indicators remained normal. Moreover, these patients had no suspected manifestations of CNS infection. Haematological and imaging examinations showed no abnormal changes after BM-MSCs infusion. Compared with previous studies, the incidence of adverse events was nearly consistent or even lower for headache, fever, nausea, and neck pain. In conclusion, repeated intrathecal allogeneic BM-MSCs are safe, feasible, and promising for the treatment of patients with neurological diseases." @default.
• W2964017448 created "2019-07-30" @default.
• W2964017448 creator A5035339681 @default.
• W2964017448 creator A5038689955 @default.
• W2964017448 creator A5041954416 @default.
• W2964017448 creator A5053220670 @default.
• W2964017448 creator A5068545245 @default.
• W2964017448 creator A5071873092 @default.
• W2964017448 creator A5075082467 @default.
• W2964017448 date "2019-07-25" @default.
• W2964017448 modified "2023-09-27" @default.
• W2964017448 title "Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases" @default.
• W2964017448 cites W1591473290 @default.
• W2964017448 cites W1698980491 @default.
• W2964017448 cites W1791032329 @default.
• W2964017448 cites W1801150000 @default.
• W2964017448 cites W1806641500 @default.
• W2964017448 cites W1940501747 @default.
• W2964017448 cites W1966388375 @default.
• W2964017448 cites W1972290090 @default.
• W2964017448 cites W1985262604 @default.
• W2964017448 cites W1987348882 @default.
• W2964017448 cites W1992369673 @default.
• W2964017448 cites W2016879629 @default.
• W2964017448 cites W2025371271 @default.
• W2964017448 cites W2041773411 @default.
• W2964017448 cites W2045961107 @default.
• W2964017448 cites W2046521512 @default.
• W2964017448 cites W2049254168 @default.
• W2964017448 cites W2049292651 @default.
• W2964017448 cites W2058473775 @default.
• W2964017448 cites W2060578350 @default.
• W2964017448 cites W2060899360 @default.
• W2964017448 cites W2070056028 @default.
• W2964017448 cites W2081628595 @default.
• W2964017448 cites W2082772089 @default.
• W2964017448 cites W2083994698 @default.
• W2964017448 cites W2099759772 @default.
• W2964017448 cites W2100608530 @default.
• W2964017448 cites W2101266160 @default.
• W2964017448 cites W2101661147 @default.
• W2964017448 cites W2127631683 @default.
• W2964017448 cites W2138093663 @default.
• W2964017448 cites W2149113453 @default.
• W2964017448 cites W2150291254 @default.
• W2964017448 cites W2156969855 @default.
• W2964017448 cites W2161315339 @default.
• W2964017448 cites W2182766838 @default.
• W2964017448 cites W2221267861 @default.
• W2964017448 cites W2234902113 @default.
• W2964017448 cites W2275494335 @default.
• W2964017448 cites W2294100217 @default.
• W2964017448 cites W2324995304 @default.
• W2964017448 cites W2539567223 @default.
• W2964017448 cites W2549739051 @default.
• W2964017448 cites W2570418357 @default.
• W2964017448 cites W2590802656 @default.
• W2964017448 cites W2607420694 @default.
• W2964017448 cites W2613577272 @default.
• W2964017448 cites W2804468842 @default.
• W2964017448 cites W2978558460 @default.
• W2964017448 cites W2982162396 @default.
• W2964017448 cites W3157419554 @default.
• W2964017448 cites W936533906 @default.
• W2964017448 doi "https://doi.org/10.1155/2019/8421281" @default.
• W2964017448 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6683773" @default.
• W2964017448 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31428161" @default.
• W2964017448 hasPublicationYear "2019" @default.
• W2964017448 type Work @default.
• W2964017448 sameAs 2964017448 @default.
• W2964017448 citedByCount "12" @default.
• W2964017448 countsByYear W29640174482019 @default.
• W2964017448 countsByYear W29640174482020 @default.
• W2964017448 countsByYear W29640174482021 @default.
• W2964017448 countsByYear W29640174482022 @default.
• W2964017448 countsByYear W29640174482023 @default.
• W2964017448 crossrefType "journal-article" @default.
• W2964017448 hasAuthorship W2964017448A5035339681 @default.
• W2964017448 hasAuthorship W2964017448A5038689955 @default.
• W2964017448 hasAuthorship W2964017448A5041954416 @default.
• W2964017448 hasAuthorship W2964017448A5053220670 @default.
• W2964017448 hasAuthorship W2964017448A5068545245 @default.
• W2964017448 hasAuthorship W2964017448A5071873092 @default.
• W2964017448 hasAuthorship W2964017448A5075082467 @default.
• W2964017448 hasBestOaLocation W29640174481 @default.
• W2964017448 hasConcept C11413529 @default.
• W2964017448 hasConcept C126322002 @default.
• W2964017448 hasConcept C142724271 @default.
• W2964017448 hasConcept C16930146 @default.
• W2964017448 hasConcept C197934379 @default.
• W2964017448 hasConcept C198826908 @default.
• W2964017448 hasConcept C2780007613 @default.
• W2964017448 hasConcept C41008148 @default.
• W2964017448 hasConcept C71924100 @default.
• W2964017448 hasConceptScore W2964017448C11413529 @default.
• W2964017448 hasConceptScore W2964017448C126322002 @default.
• W2964017448 hasConceptScore W2964017448C142724271 @default.
• W2964017448 hasConceptScore W2964017448C16930146 @default.

• next